Formula I Pyridine Compounds for Metabolic Disorder Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diabetes and insulin resistance syndrome are inadequate, causing significant morbidity and mortality due to side effects and the lack of effective management for associated conditions like fatty liver disease.
Innovation Solution
A biologically active compound of Formula I, which can be administered orally, is used to treat insulin resistance syndrome, diabetes, cachexia, hyperlipidemia, fatty liver disease, obesity, atherosclerosis, or arteriosclerosis, improving tissue fuel metabolism and reducing hyperglycemia.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If insulin releasers are used to treat NIDDM, then blood glucose control is improved, but risk of hypoglycemia increases
Solution Approach 1:
The patent employs parameter changes by developing compounds with modified chemical structures (Formula I with specific substituents R1-R6) that alter the pharmacokinetic and pharmacodynamic parameters of insulin secretion. This allows for more controlled and sustained insulin release, improving glycemic control while reducing the risk of hypoglycemic episodes compared to conventional insulin releasers.
Solution Approach 2:
The invention uses composite molecular structures combining multiple functional groups (pyridine ring, substituent patterns, stereochemical configurations) to create compounds that simultaneously achieve potent insulin secretory activity and reduced hypoglycemia risk. The composite nature of these molecules allows for fine-tuned interaction with insulin secretion mechanisms.
2Reliability
If insulin sensitizers like thiazolidinediones are used, then peripheral insulin responsiveness is improved, but side effects like weight gain and edema occur
Solution Approach 1:
The patent applies parameter changes by modifying the chemical parameters of insulin-sensitizing compounds through specific substituent patterns (R1-R6 groups) on the core pyridine structure. This allows optimization of insulin sensitivity enhancement while minimizing adverse effects on fluid balance and adipose tissue metabolism that cause edema and weight gain.
Solution Approach 2:
The invention develops orally active compounds with improved safety profiles that can be used without the severe long-term side effects of conventional thiazolidinediones. The compounds achieve their therapeutic effect transiently without causing persistent fluid retention or excessive weight gain, effectively providing short-term beneficial action without long-term harmful consequences.
3Reliability
If biguanides like metformin are used, then hepatic gluconeogenesis is attenuated, but gastrointestinal side effects occur
Solution Approach 1:
The patent employs parameter changes by developing compounds with modified molecular parameters (specific substituent configurations R1-R6) that alter the mechanism and site of action on hepatic gluconeogenesis. This allows for effective suppression of glucose production by the liver while reducing direct irritation to the gastrointestinal tract compared to conventional biguanides.
4Ease of operation
If oral therapeutic agents are developed for insulin resistance, then ease of administration is improved, but side effect profile must be managed
Solution Approach 1:
The patent applies parameter changes by optimizing the physicochemical parameters of the compounds (molecular weight, lipophilicity, pKa values through substituent selection) to ensure good oral bioavailability while simultaneously controlling the side effect profile. The specific structural parameters in Formula I are tuned to achieve appropriate absorption, distribution, metabolism, and excretion characteristics.
Solution Approach 2:
The invention develops compounds that are self-regulating in their action, where the molecular structure itself provides mechanisms to limit excessive effects. The compounds automatically adjust their activity based on physiological conditions, providing therapeutic benefit while self-limiting potential side effects without requiring complex dosing regimens or monitoring.
Data Source
AI summary
Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, polycystic ovary syndrome, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed. Formula (I) wherein n is 1 or 2; q is 0 or 1; t is 0 or 1; R1 is alkyl having from 1 to 3 carbon atoms; R2 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms; A is unsubstituted or substituted phenyl; or cycloalkyl; or a 5 or 6 membered heteroaromatic ring. Alternatively, the agent can be a pharmaceutically acceptable salt of the compound of Formula I.